These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19169682)

  • 1. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.
    Lewis JD; Sullivan LA; Byrne JA; de Riese W; Bright RK
    Cancer Immunol Immunother; 2009 Aug; 58(8):1337-49. PubMed ID: 19169682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.
    Payton LA; Lewis JD; Byrne JA; Bright RK
    Cancer Immunol Immunother; 2008 Jun; 57(6):799-811. PubMed ID: 17962942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
    Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
    Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical support for tumor protein D52 as a cancer vaccine antigen.
    Bright RK
    Hum Vaccin Immunother; 2023 Dec; 19(3):2273699. PubMed ID: 37904517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
    Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.
    Bright JD; Schultz HN; Byrne JA; Bright RK
    Oncoimmunology; 2013 Jul; 2(7):e25049. PubMed ID: 24073379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.
    Lewis JD; Payton LA; Whitford JG; Byrne JA; Smith DI; Yang L; Bright RK
    Mol Cancer Res; 2007 Feb; 5(2):133-44. PubMed ID: 17314271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed oncogenic tumor-self antigens.
    Bright RK; Bright JD; Byrne JA
    Hum Vaccin Immunother; 2014; 10(11):3297-305. PubMed ID: 25483660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
    Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
    Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).
    Lima J; Jenkins C; Guerrero A; Triozzi PL; Shaw DR; Strong TV
    Vaccine; 2005 Jan; 23(10):1273-83. PubMed ID: 15652670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
    Curran MA; Allison JP
    Cancer Res; 2009 Oct; 69(19):7747-55. PubMed ID: 19738077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.
    Gravekamp C; Leal B; Denny A; Bahar R; Lampkin S; Castro F; Kim SH; Moore D; Reddick R
    Cancer Immunol Immunother; 2008 Jul; 57(7):1067-77. PubMed ID: 18094967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.